Lumpectomy in Bangalore. INR 75,000 to 2,00,000. Mastectomy runs INR 1,00,000 to 3,50,000. Throw in immediate reconstruction and the bill jumps to INR 2,50,000 at minimum, sometimes reaching INR 8,00,000 or beyond depending on which technique is used. None of that includes what comes after. Chemotherapy, radiation and targeted therapy each carry their own cost. Most breast cancer patients in Bangalore end up spending somewhere between INR 5 lakhs and INR 15 lakhs total. The exact number depends on stage, subtype and what the pathology demands from the treatment team.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Patients deserve a straight answer on cost. Surgery is one piece. What drives the total is the full treatment plan — built from pathology, not from a price list.”

The operative bill shifts based on which procedure is chosen, the hospital and whether reconstruction happens in the same session.

• Lumpectomy: INR 75,000 to 2,00,000 at private specialist centres, with breast cancer treatment at high-volume oncology hospitals sitting toward the upper end because specialist surgical fees, advanced theatre equipment and post-operative pathology infrastructure all push the number up.
• Mastectomy: Simple mastectomy costs INR 1,00,000 to 3,50,000. Modified radical mastectomy with full axillary clearance sits at the higher end variation driven by nodal count, operative time and the length of post-operative monitoring the patient needs before discharge.
• Reconstruction: Implant reconstruction adds INR 1,00,000 to 2,50,000 on top of mastectomy. Flap reconstruction DIEP, TRAM or latissimus dorsi takes the total operative cost well past INR 3,00,000 to 8,00,000 depending on the flap technique the team performs.
• Robotic Surgery: Da Vinci-assisted procedures add INR 50,000 to 1,50,000 above conventional surgery at centres equipped with robotic oncology infrastructure, reflecting platform time and equipment use rather than an increase in surgeon fee.

Surgery is the entry point. What follows it in the treatment plan frequently costs as much again.

Most patients need systemic treatment after surgery. Each modality is a separate cost entirely outside the operative fee.

• Chemotherapy: A full course costs INR 1,00,000 to 4,00,000 for standard regimens. Individual cycles run INR 15,000 to 70,000 each and robotic cancer surgery patients needing neoadjuvant or adjuvant chemotherapy should treat this as a completely separate budget line from the surgical figure.
• Radiation: Complete course in Bangalore costs INR 90,000 to 3,50,000. IMRT and stereotactic radiation sit at the higher end compared to standard external beam, which remains available at most major private hospitals across the city at a lower per-session rate.
• Targeted Therapy: HER2 positive patients on trastuzumab face monthly drug costs of INR 50,000 to 1,00,000 for the full adjuvant course in many cases this single drug expense ends up being the largest cost component in the entire treatment bill for that subtype.
• Insurance: Comprehensive health policies and cancer-specific plans cover hospitalisation, surgery, chemotherapy and radiation. Actual out-of-pocket exposure comes down to sum insured, policy exclusions and whether the treating hospital sits on the insurer’s network list.

Total breast cancer treatment in Bangalore runs INR 3 to 5 lakhs for simple early-stage cases and INR 10 to 15 lakhs for locally advanced disease needing full multimodal treatment, and for more on choosing where to have surgery, our blog on cancer surgery in Bangalore covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to breast cancer surgery at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT and over 25 published clinical studies. Patients wanting a transparent conversation about what their surgical plan involves and what it realistically costs are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. Medijourney — Breast Cancer Treatment Cost Bangalore
2. Clinicspots — Breast Cancer Treatment Cost India 2025

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Stage 1 breast cancer is localised, small and highly treatable. Surgery alone is sufficient for some patients but not all. Whether chemotherapy, radiation or hormone therapy is added depends on tumour biology, receptor status, nodal findings and genomic risk assessment rather than stage alone. Two patients with identical Stage 1 tumour sizes can have completely different treatment plans based on what the pathology and molecular profiling reveal after surgery.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Stage 1 doesn’t automatically mean no further treatment. It means the tumour is contained. What comes after surgery is decided by biology, not just by the size on the scan.”

Surgery alone is a valid complete treatment for a specific subset of Stage 1 patients and the decision rests on several well-defined clinical criteria.

• Node Negative, Clear Margins: When the sentinel node biopsy is negative and the surgical specimen has clear margins, the primary source of risk has been removed and breast cancer treatment guidelines support observation over additional systemic treatment in selected low-risk cases.
• Low Genomic Risk Score: Oncotype DX and similar genomic assays test the tumour’s molecular profile and in HR positive, HER2 negative Stage 1 patients a low recurrence score confirms that chemotherapy adds no meaningful survival benefit over hormone therapy alone after surgery.
• Hormone Therapy Follows Lumpectomy: Even when chemotherapy is omitted, HR positive Stage 1 patients receive five years of adjuvant tamoxifen or aromatase inhibitor after surgery and this is not optional even in the lowest-risk cases because late recurrence risk persists without it.
• Radiation After Lumpectomy: Lumpectomy is always followed by radiation to the remaining breast tissue regardless of how low the systemic risk is, which means surgery alone as a complete treatment applies more commonly to mastectomy patients in this stage than to lumpectomy patients.

The key point is that surgery alone is not the same as no further treatment and even the lowest-risk Stage 1 patients require some form of ongoing management after the operation.

• HER2 Positive Gets Chemo: Even small Stage 1 HER2 positive tumours receive targeted chemotherapy with trastuzumab after surgery because the biology of HER2 positive disease carries recurrence risk that surgery alone doesn’t adequately address and robotic cancer surgery or conventional lumpectomy or mastectomy is followed by a full systemic treatment course.
• Triple Negative Gets Chemo: Stage 1 triple negative breast cancer, even small tumours, generally receives chemotherapy after surgery because no targeted therapy exists for this subtype and systemic chemotherapy is the only available tool to address microscopic systemic risk.
• High Grade Changes the Plan: A Grade 3 tumour at Stage 1 carries higher proliferative activity and recurrence risk than a Grade 1 tumour of the same size and grade is factored into the decision about whether systemic treatment adds enough benefit to justify it in that specific patient.
• Oncotype DX Decides for HR Positive: For HR positive, HER2 negative Stage 1 disease the genomic recurrence score is the single most important factor in determining whether chemotherapy adds survival benefit beyond hormone therapy alone, making this test standard rather than optional in this group.

The treatment plan after Stage 1 surgery is never one-size-fits-all and for more on how breast cancer stages determine treatment, our blog on breast cancer stages covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to Stage 1 breast cancer surgical planning including post-operative treatment sequencing decisions across all subtypes. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Patients wanting clarity on whether they need treatment beyond surgery for Stage 1 disease are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Stage 1 Breast Cancer Treatment
2. World Health Organization — Breast Cancer Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

A second opinion before cancer surgery isn’t about doubting the first doctor. It’s about confirming that the diagnosis is correct, the staging is complete and the proposed operation is what a specialist oncology centre would recommend for that case. Studies consistently show that a meaningful proportion of cancer diagnoses and treatment plans change after specialist review. For a decision this significant, getting that confirmation is not excessive caution. It’s clinical due diligence.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“A second opinion doesn’t mean the first doctor was wrong. It means the patient understands what’s at stake. Every experienced oncologist expects complex cases to be reviewed and most welcome it.”

A second opinion before cancer surgery directly addresses whether the diagnosis, staging and proposed operation are all correct for that specific case.

• Diagnosis Changes: Pathology interpretation varies between laboratories and second opinions at specialist centres identify diagnostic errors or subtype reclassifications in a clinically significant number of cases, sometimes changing the entire plan before surgery has started.
• Surgery Type Changes: A general surgeon recommending mastectomy where a breast oncologist would use lumpectomy, or open surgery being proposed where breast cancer treatment specialists would use minimally invasive approaches, are real scenarios where second opinions change what operation the patient ultimately has.
• Staging Gets Reviewed: Incomplete or incorrect staging at initial diagnosis leads to under-treatment or over-treatment and a specialist second opinion frequently identifies whether the imaging and biopsy workup was sufficient to stage the cancer correctly before committing to surgery.
• Sequence Gets Reconsidered: Some cancers benefit from chemotherapy before surgery rather than surgery first and second opinions at high-volume centres regularly identify cases where the sequence initially proposed isn’t supported by current evidence for that subtype and stage.

A second opinion doesn’t delay treatment in any harmful way. In most cases it takes days to weeks and the information it produces directly improves the surgical decision that follows.

Some clinical situations make a second opinion more urgently appropriate than others.

• Rare Cancer Types: Any diagnosis outside common presentations warrants specialist review before surgery because rare cancers are more frequently misclassified and their surgical approach requires expertise that not every centre carries.
• Complex Resectable Cases: When the surgeon describes the operation as technically difficult or uncertain in achieving clear margins, robotic cancer surgery specialists or high-volume open surgery teams often offer approaches the initial centre hasn’t considered or isn’t equipped to perform.
• Sequence Uncertainty: When the patient or family questions whether surgery first or chemotherapy first is the right approach, a second opinion at a centre with a full multidisciplinary tumour board produces a documented consensus rather than one clinician’s recommendation.
• No Tumour Board: Patients treated at centres without a functioning multidisciplinary tumour board are the group most likely to benefit from second opinion review because their initial plan wasn’t collectively reviewed before being recommended to them.

Getting a second opinion is supported by every major cancer organisation globally and for more on what the process involves, our blog on second opinion in cancer diagnosis covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to second opinion consultations across all cancer types. He heads Oncology Services across Karnataka and leads cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients wanting a specialist review of their diagnosis and proposed surgical plan before committing to an operation are seen here with every case going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Getting a Second Opinion
2. World Health Organization — Cancer Diagnosis and Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Post-mastectomy radiation therapy is not given to every patient after mastectomy. It’s recommended when pathology confirms factors that raise local recurrence risk high enough to justify chest wall and nodal irradiation after surgery. These include four or more positive lymph nodes, tumours larger than 5cm, involved surgical margins and in some cases one to three positive nodes depending on tumour biology and other risk factors. When none of these are present, mastectomy alone provides sufficient local control and radiation doesn’t add meaningful clinical benefit.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Post-mastectomy radiation is a powerful tool but it’s not for everyone. The pathology tells us who genuinely benefits and who gets the side effects without the gain.”

Radiation after mastectomy is given when specific pathological findings indicate that local recurrence risk remains elevated despite complete surgical removal.

• Four or More Nodes: When four or more axillary lymph nodes contain cancer, radiation to the chest wall and regional nodes is standard because nodal disease at this extent significantly raises local and regional recurrence risk beyond what surgery alone controls.
• Tumour Over 5cm: Large primary tumours carry higher local recurrence risk even after mastectomy and breast cancer treatment guidelines recommend post-mastectomy radiation in this group regardless of nodal status in most cases.
• Positive Margins: When cancer cells reach the cut edge of the mastectomy specimen, radiation to the chest wall is used to address residual microscopic disease that re-excision after mastectomy can’t reliably correct in the same way it can after lumpectomy.
• One to Three Positive Nodes: This group sits in a grey zone and the decision depends on tumour size, biology, grade and patient-specific risk factors, with tumour board discussion determining whether radiation adds enough benefit to justify it for that individual.

When pathology shows none of these risk factors, mastectomy alone provides adequate local control and the patient proceeds directly to systemic treatment without chest wall irradiation.

• Locally Advanced Disease: Stage 3 breast cancer almost universally gets post-mastectomy radiation because the original disease burden in the chest wall and nodes makes local control through surgery alone insufficient and robotic cancer surgery or conventional mastectomy is planned from the start with radiation as the expected next step.
• Reconstruction Timing: Post-mastectomy radiation significantly affects reconstruction outcomes and the surgical team discusses whether immediate reconstruction should proceed knowing radiation is planned, because irradiated tissue and implants don’t coexist well long term.
• Inflammatory Breast Cancer: IBC always requires post-mastectomy radiation regardless of nodal count or margin status because the disease spreads through dermal lymphatics in a pattern that local surgery alone can’t control.
• Good Pathological Response: Patients who received neoadjuvant chemotherapy and achieved complete pathological response at mastectomy represent a lower local recurrence risk group and current evidence is actively evaluating whether radiation can be safely omitted in selected cases within this group.

Post-mastectomy radiation decisions are made at tumour board and for more on mastectomy recovery timelines, our blog on mastectomy recovery covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every mastectomy including post-operative radiation planning coordination with the radiation oncology team. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Patients wanting clarity on whether radiation is part of their post-mastectomy plan are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Cancer Radiation Therapy
2. World Health Organization — Breast Cancer Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Breast cancer at 25 and at 50 are often different diseases biologically. Younger women present more frequently with aggressive subtypes, dense breast tissue and a higher chance of carrying a BRCA mutation. These factors change what operation is appropriate, what needs to be tested before surgery and what discussions must happen first. At 50, the picture shifts. Hormone receptor positive disease dominates, tumour grade tends to be lower and the surgical path is generally more straightforward from the start.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“A 25-year-old and a 50-year-old with the same tumour size often need very different operations. Age at diagnosis changes the surgical conversation before we even look at the scan.”

Younger patients carry additional clinical considerations that directly shape the surgical plan before a date is even booked.

• Aggressive Biology: Under-35 breast cancers are more often triple negative or HER2 positive and breast cancer treatment at specialist centres responds by prioritising genetic testing and subtype-specific neoadjuvant planning before the surgical approach is confirmed.
• BRCA Before Surgery: A diagnosis at 25 carries a significantly higher probability of a germline BRCA mutation than the same diagnosis at 50 and mutation status directly determines whether unilateral or bilateral mastectomy is the right operation.
• Fertility Counselling First: Young women who haven’t completed their families need oncofertility counselling before any systemic treatment starts, because certain chemotherapy regimens cause permanent ovarian failure and this conversation has to happen before the surgical plan is locked in.
• Conservation Still Possible: Lumpectomy with radiation isn’t withheld based on age alone and younger women who meet the clinical criteria for breast conservation are offered it with the same oncological confidence as older patients.

Surgical planning for younger women involves more conversations, more genetic data and longer-term considerations than the same operation for someone a generation older.

• Longer Hormones: Pre-menopausal HR positive patients receive ten years of adjuvant hormone therapy rather than five and robotic cancer surgery or conventional surgery at 25 is planned knowing ovarian suppression will likely be added and maintained for years alongside it.
• Higher Recurrence Risk: Younger age is an independent local recurrence risk factor after breast conservation and radiation planning, margin adequacy and follow-up frequency are all calibrated more carefully in women under 40 than in older patients with similar tumour characteristics.
• Bilateral Makes Sense: A 25-year-old with a BRCA mutation has 40 to 50 years of contralateral breast risk ahead of her and prophylactic removal is a clinically justified surgical option rather than an overreaction to the diagnosis at her age.
• Different Reconstruction: A 25-year-old needs reconstruction that holds up over decades of body changes while a 50-year-old has a shorter reconstruction horizon with different anatomical factors, changing the technique the surgical team recommends and the long-term plan behind it.

Age shapes every part of the surgical conversation in breast cancer and for more on breast conservation criteria, our blog on breast conserving surgery covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to breast cancer surgery across all age groups including young women with aggressive subtypes and genetic risk factors. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Patients at any age wanting a clear age-appropriate surgical plan are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Cancer in Young Women
2. World Health Organization — Breast Cancer Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.